Mer­ck­'s Keytru­da gets bil­iary tract can­cer ap­proval, brings in more pos­i­tive sur­vival da­ta in re­nal car­ci­no­ma

Mer­ck is kick­ing off No­vem­ber with two pos­i­tive re­sults for its an­ti-PD-1 ther­a­py Keytru­da — a win in a sec­ondary end­point of over­all sur­vival in re­nal cell car­ci­no­ma, and a com­bo ap­proval in bil­iary tract can­cer, al­so based on an over­all sur­vival end­point.

Mer­ck said on Wednes­day that Keytru­da is the first ther­a­py to show a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in over­all sur­vival as an ad­ju­vant ther­a­py in pa­tients with re­nal cell car­ci­no­ma who have a high risk of re­cur­rence fol­low­ing nephrec­to­my, the re­moval of one or both kid­neys.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER